Bifogade filer
Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Initiator Pharma via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
2024-05-10 08:30:00
Business highlights in Q1 2024
- In January the company announced that the company will expand to a broader Sexual Health Franchise including both male Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD) indications
- In January the company announced the decision to to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2021 (“LTI2021-program”) and to conduct a directed buyback of shares in order to sell shares to the board of directors under the LTI2021-program
- In February the company announced the decision to carry out a capital increase directed at MAC Clinical Research Finance Ltd (“MAC”) in connection with MAC’s conversion notice regarding conversion of outstanding receivable on February 20th
Business highlights after this reporting period
- Nothing to report.
Financial Highlights
Fourth Quarter (2024-01-01 – 2024-03-31) |
Net revenue were KDKK 0 (0) |
Operating loss, EBIT was KDKK -3,577 (-8,677) |
Earnings per share before and after dilution was DKK -0.08 (-0.18) |
Cash: KDKK 18,760 (24,336) |
Solidity: 97% (37%) |
Solidity: equity divided by assets.
The Board of Directors have decided that interim reports will be published in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/